{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:00:47Z","timestamp":1776542447089,"version":"3.51.2"},"reference-count":183,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.bbi.2011.05.014","type":"journal-article","created":{"date-parts":[[2011,6,5]],"date-time":"2011-06-05T14:53:20Z","timestamp":1307285600000},"page":"1507-1518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Anti-inflammatory signaling in schizophrenia"],"prefix":"10.1016","volume":"25","author":[{"given":"Urs","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2011.05.014_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.9.1.1","article-title":"The role of serotonin in the pathophysiology and treatment of schizophrenia","volume":"9","author":"Abi-Dargham","year":"1997","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0010","first-page":"1356","article-title":"Interleukin-1 beta stimulates tyrosine hydroxylase activity in the median eminence","volume":"5","author":"Abreu","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbi.2011.05.014_b0015","doi-asserted-by":"crossref","unstructured":"Akagbosu, C.O., Evans, G.C., Gulick, D., Suckow, R.F., Bucci, D.J., 2010. Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr. Bull., in press (Epub ahead of print [PMID: 21172906]).","DOI":"10.1093\/schbul\/sbq151"},{"key":"10.1016\/j.bbi.2011.05.014_b0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(98)00140-6","article-title":"Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration","volume":"37","author":"Akiyama","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0030","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0889-1591(02)00011-9","article-title":"Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes","volume":"16","author":"Anisman","year":"2002","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2011.05.014_b0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1359-6101(02)00020-5","article-title":"The balance between IL-1 and IL-1Ra in disease","volume":"13","author":"Arend","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbi.2011.05.014_b0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.immunol.16.1.27","article-title":"Interleukin-1 receptor antagonist: role in biology","volume":"16","author":"Arend","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.biopsych.2006.12.021","article-title":"Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia","volume":"62","author":"Arion","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0050","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1471-4159.1977.tb07780.x","article-title":"Correlation between tyrosine hydroxylase activity and catecholamine concentration or turnover in brain regions","volume":"29","author":"Bacopoulos","year":"1977","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2011.05.014_b0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrn2054","article-title":"The neuropoietic cytokine family in development, plasticity, disease and injury","volume":"8","author":"Bauer","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0304-3940(99)00545-5","article-title":"Evidence for activation of microglia in patients with psychiatric illnesses","volume":"271","author":"Bayer","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbi.2011.05.014_b0070","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1586\/ern.09.59","article-title":"Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy","volume":"9","author":"Bernstein","year":"2009","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.bbi.2011.05.014_b0075","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/187152809789352221","article-title":"Anti-inflammatory drugs in psychiatry","volume":"8","author":"Berthold-Losleben","year":"2009","journal-title":"Inflamm. Allergy. Drug Targets"},{"key":"10.1016\/j.bbi.2011.05.014_b0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0085","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0006-3223(01)01324-5","article-title":"Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia","volume":"51","author":"Bocchio Chiavetto","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbi.2011.05.014_b0095","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1017\/S1461145709000315","article-title":"Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia","volume":"12","author":"Bresee","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2011.05.014_b0100","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2007.12.007","article-title":"Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans","volume":"63","author":"Brydon","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0105","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1080\/15622970903144004","article-title":"Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia","volume":"10","author":"Bulut","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.41.1.237","article-title":"Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence","volume":"41","author":"Carlsson","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbi.2011.05.014_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0278-5846(01)00221-4","article-title":"Cytokine profiles in schizophrenic patients treated with risperidone: a 3month follow-up study","volume":"26","author":"Cazzullo","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbr.2006.03.006","article-title":"Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding","volume":"170","author":"Chess","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/schbul\/sbl033","article-title":"Elevations of endogenous kynurenic acid produce spatial working memory deficits","volume":"33","author":"Chess","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2011.05.014_b0130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000148197","article-title":"Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia","volume":"15","author":"Coelho","year":"2008","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.bbi.2011.05.014_b0135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jneuroim.2010.11.006","article-title":"Plasma cytokine concentrations associated with HIV\/hepatitis C coinfection are related to attention, executive and psychomotor functioning","volume":"233","author":"Cohen","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0140","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1192\/bjp.174.6.520","article-title":"Fever and acute brief psychosis in urban and rural settings in north India","volume":"174","author":"Collins","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0145","doi-asserted-by":"crossref","unstructured":"Condray, R., Dougherty, G.G., Keshavan, M.S., Reddy, R.D., Haas, G.L., Montrose, D.M., Matson, W.R., McEvoy, J., Kaddurah-Daouk, R., Yao, J.K., 2011. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol, in press (Epub ahead of print [PMID: 21275080]).","DOI":"10.1017\/S1461145710001689"},{"key":"10.1016\/j.bbi.2011.05.014_b0150","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.4049\/jimmunol.0901871","article-title":"Induction of TGF-beta 1, not regulatory T cells, impairs antiviral immunity in the lung following bone marrow transplant","volume":"184","author":"Coomes","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0155","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1196\/annals.1300.020","article-title":"Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia","volume":"1003","author":"Coyle","year":"2003","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.bbi.2011.05.014_b0160","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1371\/journal.pone.0000692","article-title":"Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms","volume":"2","author":"Craddock","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.bbi.2011.05.014_b0165","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1128\/CMR.10.4.742","article-title":"A primer on cytokines: sources, receptors, effects, and inducers","volume":"10","author":"Curfs","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bbi.2011.05.014_b0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci"},{"key":"10.1016\/j.bbi.2011.05.014_b0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s004300050031","article-title":"Cellular immune reactions directed against Toxoplasma gondii with special emphasis on the central nervous system","volume":"185","author":"D\u00e4ubener","year":"1997","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2007.03.022","article-title":"C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia","volume":"93","author":"Dickerson","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0185","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","article-title":"Redox dysregulation, neurodevelopment, and schizophrenia","volume":"19","author":"Do","year":"2009","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bbi.2011.05.014_b0190","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2967\/jnumed.109.066647","article-title":"Neuroinflammation in schizophrenia-related psychosis: a PET study","volume":"50","author":"Doorduin","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbi.2011.05.014_b0195","doi-asserted-by":"crossref","unstructured":"Drexhage, R.C., Hoogenboezem, T.A., Cohen, D., Versnel, M.A., Nolen, W.A., van Beveren, N.J., Drexhage, H.A., 2011. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int. J. Neuropsychopharmacol., in press (Epub ahead of print [PMID: 21255481]).","DOI":"10.1017\/S1461145710001653"},{"key":"10.1016\/j.bbi.2011.05.014_b0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/ern.09.144","article-title":"The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder","volume":"10","author":"Drexhage","year":"2010","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.bbi.2011.05.014_b0205","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.bbi.2011.05.014_b0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cnr.2006.04.002","article-title":"Effects of cytokines and infections on brain neurochemistry","volume":"6","author":"Dunn","year":"2006","journal-title":"Clin. Neurosci. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v14.i1.10","article-title":"Cognitive impairment in schizophrenia is the core of the disorder","volume":"14","author":"Elvev\u00e5g","year":"2000","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.bbi.2011.05.014_b0220","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/14737175.7.7.789","article-title":"Inflammation and schizophrenia","volume":"7","author":"Fan","year":"2007","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.bbi.2011.05.014_b0225","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/schbul\/sbn187","article-title":"The neurodevelopmental hypothesis of schizophrenia","volume":"35","author":"Fatemi","year":"2009","journal-title":"Revisited. Schizophr. Bull."},{"key":"10.1016\/j.bbi.2011.05.014_b0230","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","article-title":"Metabolic profile of antipsychotic-naive individuals with non-affective psychosis","volume":"194","author":"Fernandez-Egea","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0235","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archgenpsychiatry.2011.2","article-title":"Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis","volume":"68","author":"Foley","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0240","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Gabay","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbi.2011.05.014_b0245","series-title":"Inflammation: Basic Principles and Clinical Correlates","author":"Gallin","year":"1999"},{"key":"10.1016\/j.bbi.2011.05.014_b0250","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.neubiorev.2008.04.001","article-title":"Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms","volume":"32","author":"Garc\u00eda-Bueno","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbi.2011.05.014_b0255","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1469-7580.2010.01231.x","article-title":"When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits","volume":"217","author":"Garey","year":"2010","journal-title":"J. Anat."},{"key":"10.1016\/j.bbi.2011.05.014_b0260","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/BOR.0b013e3283373fa0","article-title":"Actual status of antiinterleukin-1 therapies in rheumatic diseases","volume":"22","author":"Geyer","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bbi.2011.05.014_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0140525X00065055","article-title":"The neuropsychology of schizophrenia","volume":"14","author":"Gray","year":"1991","journal-title":"Behav. Brain Sci."},{"key":"10.1016\/j.bbi.2011.05.014_b0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.intimp.2010.02.012","article-title":"Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists","volume":"10","author":"Greineisen","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbi.2011.05.014_b0275","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-3956(99)00021-7","article-title":"Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis","volume":"33","author":"Haack","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0280","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1046\/j.1460-9568.2002.01936.x","article-title":"Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-alpha: peripheral and central mechanisms","volume":"15","author":"Hayley","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2005.06.054","article-title":"Interleukin-10\u20131082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study","volume":"394","author":"He","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbi.2011.05.014_b0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01735051","article-title":"T-lymphocyte subpopulations in schizophrenic patients","volume":"239","author":"Henneberg","year":"1990","journal-title":"Eur. Arch. Psychiatry Neurol. Sci."},{"key":"10.1016\/j.bbi.2011.05.014_b0295","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0300","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/schbul\/sbm010","article-title":"A controlled prospective study of toxoplasma gondii infection in individuals with schizophrenia: beyond seroprevalence","volume":"33","author":"Hinze-Selch","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2011.05.014_b0305","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbr.2008.06.032","article-title":"Lipopolysaccharide-induced immune activation impairs attention but has little effect on short-term working memory","volume":"194","author":"Holden","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0310","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1399-5618.2009.00757.x","article-title":"Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor","volume":"11","author":"Hope","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.bbi.2011.05.014_b0315","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 1","key":"10.1016\/j.bbi.2011.05.014_b0320","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1002\/jmv.10320","article-title":"IL-10 gene polymorphism and herpesvirus infections","volume":"70","author":"Hurme","year":"2003","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bbi.2011.05.014_b0325","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.yco.0000218603.25346.8f","article-title":"Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations","volume":"19","author":"Jarskog","year":"2006","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","article-title":"Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions","volume":"78","author":"Javitt","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbi.2011.05.014_b0335","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.schres.2009.06.003","article-title":"Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis","volume":"113","author":"Jindal","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0340","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.pnpbp.2004.05.027","article-title":"Adverse effects of cannabis on health: an update of the literature since 1996","volume":"28","author":"Kalant","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.ajp.160.1.13","article-title":"Psychosis as a state of aberrant salience. a framework linking biology, phenomenology, and pharmacology in schizophrenia","volume":"160","author":"Kapur","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","article-title":"Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics","volume":"44","author":"Kim","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0355","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.pnpbp.2004.05.047","article-title":"Th1, Th2 and Th3 cytokine alteration in schizophrenia","volume":"28","author":"Kim","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0360","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000213565","article-title":"Cytokine changes and tryptophan metabolites in medication-na\u00efve and medication-free schizophrenic patients","volume":"59","author":"Kim","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.bbi.2011.05.014_b0365","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.icb.7100113","article-title":"SIL-6R: more than an agonist?","volume":"86","author":"Kn\u00fcpfer","year":"2008","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bbi.2011.05.014_b0370","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0375","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2008.03.002","article-title":"The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2)","volume":"31","author":"Lan","year":"2008","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bbi.2011.05.014_b0380","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.4049\/jimmunol.168.7.3402","article-title":"Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter","volume":"168","author":"Lang","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0385","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/brbi.2001.0643","article-title":"Behavioral effects of cytokines","volume":"15","author":"Larson","year":"2001","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2011.05.014_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005344-199401000-00026","article-title":"Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist","volume":"23","author":"Latini","year":"1994","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bbi.2011.05.014_b0395","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","article-title":"Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients","volume":"33","author":"Lavoie","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2011.05.014_b0400","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0405","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0410","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/archneur.63.10.1372","article-title":"Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations","volume":"63","author":"Lewis","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbi.2011.05.014_b0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","article-title":"The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6","volume":"32","author":"Lin","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0420","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/00048670903487209","article-title":"Increased risk of acute myocardial infarction after acute episode of schizophrenia: 6 year follow-up study","volume":"44","author":"Lin","year":"2010","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0425","doi-asserted-by":"crossref","unstructured":"Linderholm, K.R., Skogh, E., Olsson, S.K., Dahl, M.L., Holtze, M., Engberg, G., Samuelsson, M., Erhardt, S., 2010. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull., press (Epub ahead of print [PMID: 20729465]).","DOI":"10.1093\/schbul\/sbq086"},{"key":"10.1016\/j.bbi.2011.05.014_b0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2008.10.024","article-title":"Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis","volume":"176","author":"Liu","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0435","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0440","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0920-9964(96)00029-1","article-title":"Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs","volume":"21","author":"Maes","year":"1996","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0450","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","article-title":"Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine","volume":"89","author":"Maes","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbi.2011.05.014_b0455","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.psychres.2006.06.004","article-title":"T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment","volume":"152","author":"Maino","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0460","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0447.1998.tb09974.x","article-title":"Onset of acute psychotic states in India: a study of sociodemographic, seasonal and biological factors","volume":"97","author":"Malhotra","year":"1998","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbi.2011.05.014_b0465","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0470","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/01.psy.0000238451.22174.92","article-title":"Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers","volume":"68","author":"Marsland","year":"2006","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.bbi.2011.05.014_b0475","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0074-7742(06)78008-4","article-title":"Schizophrenia and the alpha7 nicotinic acetylcholine receptor","volume":"78","author":"Martin","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbi.2011.05.014_b0480","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neubiorev.2008.10.005","article-title":"Evidence for a cytokine model of cognitive function","volume":"33","author":"McAfoose","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbi.2011.05.014_b0485","doi-asserted-by":"crossref","first-page":"26R","DOI":"10.1203\/PDR.0b013e318212c196","article-title":"Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation?","volume":"69","author":"Meyer","year":"2011","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0490","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2174\/187152708786441858","article-title":"Clinical potential of minocycline for schizophrenia","volume":"7","author":"Miyaoka","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.bbi.2011.05.014_b0495","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/WNF.0b013e3181593d45","article-title":"Minocycline as adjunctive therapy for schizophrenia: an open-label study","volume":"31","author":"Miyaoka","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bbi.2011.05.014_b0500","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eurpsy.2007.03.010","article-title":"Clinical evaluation of negative symptoms in schizophrenia","volume":"22","author":"M\u00f6ller","year":"2007","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0505","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1819.2009.01945.x","article-title":"Cytokines and schizophrenia: Microglia hypothesis of schizophrenia","volume":"63","author":"Monji","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0510","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.npp.1300342","article-title":"Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers","volume":"29","author":"Morgan","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2011.05.014_b0515","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(02)00023-8","article-title":"Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation","volume":"82","author":"Moustakas","year":"2002","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bbi.2011.05.014_b0520","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0165-1781(91)90072-W","article-title":"Cellular immunity in schizophrenic patients before and during neuroleptic treatment","volume":"37","author":"M\u00fcller","year":"1991","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0525","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0924-9338(97)84789-X","article-title":"Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients","volume":"12","author":"M\u00fcller","year":"1997","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0530","doi-asserted-by":"crossref","DOI":"10.1007\/BF02922260","article-title":"Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia","volume":"247","author":"M\u00fcller","year":"1997","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0535","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"M\u00fcller","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0540","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/138161211795049552","article-title":"Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects","volume":"17","author":"M\u00fcller","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbi.2011.05.014_b0545","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1749-6632.2000.tb05410.x","article-title":"The immune system and schizophrenia. An integrative view","volume":"917","author":"M\u00fcller","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.bbi.2011.05.014_b0550","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"M\u00fcller","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0555","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00406-004-0548-4","article-title":"Clinical effects of COX-2 inhibitors on cognition in chizophrenia","volume":"255","author":"M\u00fcller","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0560","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2174\/138161208784480243","article-title":"COX-2 inhibition in schizophrenia and major depression","volume":"14","author":"M\u00fcller","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbi.2011.05.014_b0565","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.mp.4002006","article-title":"The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression","volume":"12","author":"M\u00fcller","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0570","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/157339510791823673","article-title":"Immune system and schizophrenia","volume":"6","author":"M\u00fcller","year":"2010","journal-title":"Curr. Immunol. Rev."},{"key":"10.1016\/j.bbi.2011.05.014_b0575","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.coph.2006.01.010","article-title":"Understanding and exploiting the endogenous interleukin-10\/STAT3-mediated anti-inflammatory response","volume":"6","author":"Murray","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbi.2011.05.014_b0580","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4049\/jimmunol.158.1.315","article-title":"T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection","volume":"158","author":"Murray","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0585","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000111535","article-title":"Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia","volume":"56","author":"Na","year":"2007","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.bbi.2011.05.014_b0590","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0920-9964(97)00059-5","article-title":"A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?","volume":"26","author":"Naudin","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60386-7","article-title":"Biology of the interleukin-2 receptor","volume":"70","author":"Nelson","year":"1998","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0600","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2005.07.013","article-title":"Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia","volume":"80","author":"Nilsson","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0605","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jpsychires.2007.04.002","article-title":"TGFBR2 gene expression and genetic association with schizophrenia","volume":"42","author":"Numata","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0610","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2249.2007.03533.x","article-title":"Increased weight loss with reduced viral replication in interleukin-10 knock-out mice infected with murine cytomegalovirus","volume":"151","author":"Oakley","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0615","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0165-1781(96)02824-7","article-title":"Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder","volume":"65","author":"O\u2019Donnell","year":"1996","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0620","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oxfordjournals.schbul.a033407","article-title":"At issue: schizophrenia and rheumatoid arthritis: the negative association revisited","volume":"25","author":"Oken","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2011.05.014_b0625","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine signaling modules in inflammatory responses","volume":"28","author":"O\u2019Shea","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.bbi.2011.05.014_b0630","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.neuroimage.2005.05.035","article-title":"Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene","volume":"27","author":"Papiol","year":"2005","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbi.2011.05.014_b0635","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/clc.4960280409","article-title":"Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction","volume":"28","author":"Patti","year":"2005","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.bbi.2011.05.014_b0640","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.pnpbp.2008.07.017","article-title":"Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia","volume":"32","author":"Pedersen","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0645","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/j.1440-1614.2006.01877.x","article-title":"Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders","volume":"40","author":"Phillips","year":"2006","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0650","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-3956(00)00032-7","article-title":"Effects of antipsychotic drugs on cytokine networks","volume":"34","author":"Pollm\u00e4cher","year":"2000","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0655","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0660","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jnen\/59.2.137","article-title":"Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics","volume":"59","author":"Radewicz","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbi.2011.05.014_b0665","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.immunol.021908.132528","article-title":"Microglial physiology: unique stimuli, specialized responses","volume":"27","author":"Ransohoff","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0670","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.biopsych.2005.02.024","article-title":"Celecoxib augmentation of continuously ill patients with schizophrenia","volume":"57","author":"Rapaport","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0675","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2202-12-13","article-title":"Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls","volume":"12","author":"Reale","year":"2011","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0680","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0966-842X(00)01919-3","article-title":"Hijacking and exploitation of IL-10 by intracellular pathogens","volume":"9","author":"Redpath","year":"2001","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bbi.2011.05.014_b0685","first-page":"F76","article-title":"S100B in schizophrenia: an update","volume":"28","author":"Rothermundt","year":"2009","journal-title":"Gen. Physiol. Biophys."},{"key":"10.1016\/j.bbi.2011.05.014_b0690","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/15622970410029905","article-title":"Search for atypical lymphocytes in schizophrenia","volume":"5","author":"Rudolf","year":"2004","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0695","doi-asserted-by":"crossref","unstructured":"Sathyasaikumar, K.V., Stachowski, E.K., Wonodi, I., Roberts, R.C., Rassoulpour, A., McMahon, R.P., Schwarcz, R., 2010. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull., in press (Epub ahead of print [PMID: 21036897]).","DOI":"10.1093\/schbul\/sbq112"},{"key":"10.1016\/j.bbi.2011.05.014_b0700","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.4049\/jimmunol.157.9.4045","article-title":"In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection","volume":"157","author":"Scharton-Kersten","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0705","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0710","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nature08192","article-title":"Common variants on chromosome 6p22.1 are associated with schizophrenia","volume":"460","author":"Shi","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2011.05.014_b0715","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jir.1997.17.145","article-title":"Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction","volume":"17","author":"Shibata","year":"1997","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0720","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0924-977X(01)00096-7","article-title":"Abnormal thermoregulation in drug-free male schizophrenia patients","volume":"11","author":"Shiloh","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2011.05.014_b0725","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1517\/14656566.5.10.2053","article-title":"Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia","volume":"5","author":"Silver","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bbi.2011.05.014_b0730","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.psychres.2004.04.012","article-title":"Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients","volume":"134","author":"Sirota","year":"2005","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0735","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0306-9877(91)90064-6","article-title":"The immune system is a key factor in the etiology of psychosocial disease","volume":"34","author":"Smith","year":"1991","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbi.2011.05.014_b0740","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0920-9964(99)00116-4","article-title":"Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist","volume":"42","author":"Song","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0745","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia","volume":"65","author":"Song","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0755","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0920-9964(98)00175-3","article-title":"T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients","volume":"38","author":"Sperner-Unterweger","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0760","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","article-title":"Common variants conferring risk of schizophrenia","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2011.05.014_b0765","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpsychires.2006.10.013","article-title":"Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide","volume":"42","author":"Steiner","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0770","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00406-010-0098-x","article-title":"Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity","volume":"260","author":"Steiner","year":"2010","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2011.05.014_b0775","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00401-006-0090-8","article-title":"Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization","volume":"112","author":"Steiner","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbi.2011.05.014_b0780","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archpsyc.1982.04290100011003","article-title":"Neuropathology of schizophrenia","volume":"39","author":"Stevens","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0785","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.pnpbp.2008.12.006","article-title":"Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice","volume":"33","author":"Sugino","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0790","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.psychres.2008.07.021","article-title":"Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in a general population","volume":"175","author":"Suvisaari","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0795","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.3128869","article-title":"Interferon-gamma: the major mediator of resistance against Toxoplasma gondii","volume":"240","author":"Suzuki","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.bbi.2011.05.014_b0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Epidemiology and etiology. 2","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0810","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0920-9964(00)00007-4","article-title":"Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients","volume":"47","author":"Theodoropoulou","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0815","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00023210-200620110-00001","article-title":"Cytomegalovirus and schizophrenia","volume":"20","author":"Torrey","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbi.2011.05.014_b0820","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3201\/eid0911.030143","article-title":"Toxoplasma gondii and schizophrenia","volume":"9","author":"Torrey","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.bbi.2011.05.014_b0825","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0168-0102(03)00093-2","article-title":"A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients","volume":"46","author":"Toyooka","year":"2003","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0830","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/1469-8986.00072","article-title":"Heart rate variability in acute psychosis","volume":"40","author":"Valkonen-Korhonen","year":"2003","journal-title":"Psychophysiology"},{"key":"10.1016\/j.bbi.2011.05.014_b0835","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","article-title":"Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study","volume":"64","author":"van Berckel","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0840","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0165-1781(99)00053-0","article-title":"Elevated interleukin-6 in schizophrenia","volume":"87","author":"van Kammen","year":"1999","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0845","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0893-133X(96)00143-1","article-title":"Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients","volume":"16","author":"Vawter","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2011.05.014_b0850","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4088\/JCP.08m04508","article-title":"Metabolic risk factors in drug-naive patients with first-episode psychosis","volume":"70","author":"Verma","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0855","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.150.5.1979","article-title":"Activation of tumor necrosis factor-alpha production from human neutrophils by IL-2 via IL-2-R beta","volume":"150","author":"Wei","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2011.05.014_b0860","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.bbi.2011.05.014_b0865","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1359786810384639","article-title":"Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J","volume":"24","author":"Wildgust","year":"2010","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.bbi.2011.05.014_b0870","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/schbul\/sbq002","article-title":"Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia","volume":"36","author":"Wonodi","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2011.05.014_b0875","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2010.02.1031","article-title":"Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population","volume":"120","author":"Xu","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0880","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.pnpbp.2004.05.033","article-title":"Proposal for a noradrenaline hypothesis of schizophrenia","volume":"28","author":"Yamamoto","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0885","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pharmthera.2008.08.004","article-title":"Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia","volume":"120","author":"Yang","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbi.2011.05.014_b0890","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/mp.2008.5","article-title":"Are some cases of psychosis caused by microbial agents? A review of the evidence","volume":"13","author":"Yolken","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.05.014_b0895","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/jb\/mvq043","article-title":"Cellular and molecular basis for the regulation of inflammation by TGF-beta","volume":"147","author":"Yoshimura","year":"2010","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbi.2011.05.014_b0900","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.cr.7310004","article-title":"Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells","volume":"16","author":"Young","year":"2006","journal-title":"Cell Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0905","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2004.01.001","article-title":"An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population","volume":"71","author":"Yu","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0910","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0006-8993(94)90006-X","article-title":"Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6","volume":"643","author":"Zalcman","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.bbi.2011.05.014_b0915","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.npp.1300756","article-title":"Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics","volume":"30","author":"Zhang","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2011.05.014_b0920","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-008-1447-6","article-title":"Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics","volume":"204","author":"Zhang","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbi.2011.05.014_b0925","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0920-9964(01)00296-1","article-title":"Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology","volume":"57","author":"Zhang","year":"2002","journal-title":"Schizophr. Res."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159111001930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159111001930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:26:57Z","timestamp":1760167617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159111001930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":183,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0889159111001930"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2011.05.014","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-inflammatory signaling in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2011.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}